Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2010

01-05-2010 | Poster presentation

Effect of intermittent versus continuous energy restriction on weight loss and breast cancer risk biomarkers

Authors: M Harvie, M Pegington, J Cuzick, J Frystyk, A Flyvbjerg, S Jebb, M Mattson, A Howell

Published in: Breast Cancer Research | Special Issue 1/2010

Login to get access

Excerpt

The problems of adherence to energy restriction in humans are well known. Animal data suggest intermittent energy restriction (IER) is comparable with or better for preventing breast cancer than continuous restriction (CER). …
Metadata
Title
Effect of intermittent versus continuous energy restriction on weight loss and breast cancer risk biomarkers
Authors
M Harvie
M Pegington
J Cuzick
J Frystyk
A Flyvbjerg
S Jebb
M Mattson
A Howell
Publication date
01-05-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2525

Other articles of this Special Issue 1/2010

Breast Cancer Research 1/2010 Go to the issue

Poster presentation

Thioredoxin and related redox systems as targets in breast cancer

Poster presentation

Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells

Oral presentation

Differentiation therapy: targeting breast cancer stem cells to reduce resistance to radiotherapy and chemotherapy

Poster presentation

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy

Oral presentation

Transforming growth factor-beta co-receptor endoglin suppresses breast cancer invasion and metastasis

Oral presentation

New regulators of the BRCA1 response to genotoxic stress
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits